RxDoctor Payments Data

Michael Peters, MD

Family Medicine · Naperville, ILNPI 1023005097

Payments from drug & device makers

$893in general payments, 2019–2025

Across 39 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$395
  • Novo Nordisk$235
  • Amarin Pharma, Inc.$128
  • AbbVie$28
  • Astellas Pharma Global Development$24
  • Johnson & Johnson$23
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$893100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$92,158
Medicare patients
127
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$54,941
OzempicSemaglutide22$32,387
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,488
SynthroidLevothyroxine Sodium39$4,732
Rivastigmine17$4,501
Breo ElliptaFluticasone/Vilanterol11$4,494
Rosuvastatin Calcium237$3,108
SimbrinzaBrinzolamide/Brimonidine Tart11$2,496
Morphine Sulfate ErMorphine Sulfate14$2,266
Levothyroxine Sodium136$1,817
Telmisartan47$1,449
Tamsulosin Hcl53$1,327
Ibandronate Sodium39$1,241
Memantine Hcl ErMemantine Hcl26$1,206
Losartan Potassium90$1,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$395$54,94135 claims
Novo NordiskOzempic$235$32,38722 claims
AbbVieSynthroid$28$4,73239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →